JAGX · Jaguar Health, Inc.
$0.74
+0.01 (+1.57%)
At close · Sep 2
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions, along with recurring operating losses and an accumulated deficit, raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these consolidated financial statements. While management believes this infusion improves our liquidity, it does not fully alleviate the conditions that raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements.”View the 10-Q filed Aug 19, 2026
Market Cap
$3.78M
Shares
5.17M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$11.51M
-1.5%
FY2025
Net Income
-$53.58M
-39.2%
FY2025
Gross Margin
67.21%
-16.1pp
FY2025
Operating Margin
-398.82%
-135.1pp
FY2025
Diluted EPS
-$803.95
+82.4%
FY2025
Operating Cash Flow
-$23.69M
+19.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $27.82M | $11.51M | $11.69M | $9.76M | $11.96M | $4.34M | $9.39M | $5.78M | $4.42M | $4.36M | $141.52K | $258.38K | $0 | |
| $4.92M | $3.77M | $1.96M | $2.04M | $2.02M | $2.33M | $3.28M | $3.82M | $2.77M | $880.41K | $51.97K | $123.46K | — | |
| $22.89M | $7.74M | $9.73M | $7.72M | $9.94M | $2M | $6.11M | $1.96M | $1.65M | $3.48M | $89.56K | $134.92K | — | |
| — | 67.21% | 83.27% | 79.13% | 83.11% | 46.18% | 65.05% | 33.92% | 37.37% | 79.81% | 63.28% | 52.22% | — | |
| $25.24M | $24.97M | $16.54M | $18.6M | $17.65M | $15.08M | $6.41M | $5.82M | $5.15M | $4.27M | $7.21M | $6.48M | $4.22M | |
| $5.18M | $9.24M | $7.69M | $6.46M | $8.84M | $8.89M | $6.61M | $6.94M | $9.83M | $3.08M | $485.44K | $765.09K | — | |
| $17.58M | $18.64M | $16.33M | $16.59M | $17.87M | $17.1M | $14.39M | $13.5M | $12.28M | $11.25M | $5.98M | $5.34M | $4.1M | |
| $1.9M | $1.9M | $1.9M | $2M | $1.8M | $1.7M | $1.7M | $1.7M | $1.69M | $702.78K | — | — | — | |
| $1.9M | $1.91M | $1.9M | $2.01M | $1.98M | $1.72M | $1.73M | $1.74M | $1.32M | $584.34K | $47.49K | $5155 | — | |
| $36.67M | — | — | — | — | — | — | — | $35.24M | $38.61M | $13.73M | $12.7M | $8.32M | |
| $53.71M | $57.42M | $42.52M | $44.05M | $46.37M | $45.04M | $36.03M | $34.72M | $35.24M | — | — | — | — | |
| -$25.9M | -$45.91M | -$30.83M | -$34.29M | -$34.42M | -$40.71M | -$26.65M | -$28.95M | -$30.82M | -$34.25M | -$13.59M | -$12.45M | -$8.32M | |
| — | -398.82% | -263.76% | -351.31% | -287.85% | -939.05% | -283.93% | -501.26% | -697.98% | -785.27% | -9599.84% | -4816.67% | — | |
| -$23.99M | -$44M | -$28.93M | -$32.28M | -$32.43M | -$38.99M | -$24.92M | -$27.21M | -$29.5M | -$33.66M | -$13.54M | -$12.44M | — | |
| $998K | $67K | $231K | $6.38M | $12.72M | $8.42M | $2.79M | $5.73M | $2.63M | $1.21M | $985.55K | $3.32M | $345.34K | |
| $192K | $43K | $51K | $200K | $950K | -$765K | $190K | $81K | $315.69K | $88.55K | -$11.05K | -$27.28K | — | |
| -$123K | -$162K | -$138K | -$51K | — | — | — | — | — | — | — | — | — | |
| -$36.92M | -$54M | -$39.25M | -$41.9M | -$48.4M | -$52.6M | -$33.81M | -$38.53M | -$32.15M | -$35.15M | -$14.73M | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $10K | — | -$13.18M | — | — | — | |
| $17.02M | -$53.58M | -$38.49M | -$41.9K | -$48.4K | -$52.6K | -$33.81M | -$38.54M | -$32.15M | -$21.97M | -$14.73M | -$16.29M | -$8.61M | |
| — | -465.42% | -329.3% | -0.43% | -0.4% | -1.21% | -360.25% | -667.34% | -727.92% | -503.73% | -10410.87% | -6305.24% | — | |
| -$524K | -$563K | -$759K | -$601K | -$941K | -$5000 | — | — | — | — | — | — | — | |
| -$52.42M | -$53.58M | -$38.49M | -$41.3M | -$47.45M | -$52.6M | -$38.65M | — | -$32.15M | -$21.97M | -$14.73M | -$16.64M | -$9.26M | |
| -$52.94M | -$53.94M | -$38.31M | -$41.27M | -$48.13M | — | — | — | — | — | — | — | — | |
| USD/shares | $110.14 | -$803.95 | -$4,574.15 | -$93,735.95 | -$1,899,450.00 | -$4,631,550.00 | -$11,812,500.00 | — | — | — | — | — | — |
| USD/shares | $110.14 | -$803.95 | -$4,574.15 | -$93,735.95 | -$1,899,450.00 | -$4,631,550.00 | -$11,812,500.00 | — | — | — | — | — | — |
| shares | — | 66.64K | 8415.2571 | 440.6 | 24.9813 | 11.3553 | 3.2713 | 0.4203 | 0.0178 | 0.2451 | 0.9271 | 0.5209 | 0.2416 |
| shares | — | 66.64K | 8415.2571 | 440.6 | 24.9813 | 11.3553 | 3.2713 | 0.4203 | 0.0178 | 0.2451 | 0.9271 | 0.5209 | 0.2416 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.02×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 136 similar-size Biotechnology companies (of 513 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Human Health Segment | $11,158,000 | $11,374,000 | $9,588,000 | $11,741,000 | $4,273,000 | $9,309,000 |
| Animal Health Segment | $353,000 | $315,000 | $173,000 | $215,000 | $62,000 | $76,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $11,339,000 | $11,560,000 | $9,761,000 | — | $4,335,000 | — |
| Mytesi | $11,000,000 | $11,300,000 | $9,600,000 | $11,700,000 | $4,300,000 | $9,300,000 |
| License | $172,000 | $129,000 | — | — | — | — |
| Canalevia | $148,000 | $160,000 | $130,000 | $167,000 | — | — |
| Neonorm | $35,000 | $28,000 | $42,000 | $48,000 | $62,000 | $76,000 |